Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Type
Public
HQ
Bagsvaerd, DK
Founded
1923
Size (employees)
42,076 (est)+2%
Novo Nordisk was founded in 1923 and is headquartered in Bagsvaerd, DK
Report incorrect company information

Key People/Management at Novo Nordisk

Lars Rebien Sørensen

Lars Rebien Sørensen

President & Chief Executive Officer
Jesper Brandgaard

Jesper Brandgaard

EVP and Chief Financial Officer
Maziar Mike Doustdar

Maziar Mike Doustdar

EVP of International Operations
Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen

EVP Corporate Developemnt
Show more

Novo Nordisk Office Locations

Novo Nordisk has offices in Pensacola, Knoxville, Detroit, Grand Rapids and in 137 other locations
Bagsvaerd, DK (HQ)
Novo Nordisk A/S Novo Allé
Mississauga, CA
300-2680 Skymark Avenue, Floor 3
Beijing, CN
18F, East Tower, World Financial Center, No. 1 East 3rd Ring Middle Road, Chaoyang District
Mainz, DE
Brucknerstrasse 1
Bangalore, IN
Plot No.32, 47-50, EPIP Area, Whitefield
Tokyo, JP
Meiji Yasuda Seimei Bldg. 2-1-1, Marunouchi, Chiyoda-ku
Show all (141)
Report incorrect company information

Novo Nordisk Financials and Metrics

Novo Nordisk Revenue

Market capitalization (16-Aug-2018)

115.3 b

Closing stock price (16-Aug-2018)

47.8
Novo Nordisk's current market capitalization is $115.3 b.
Show all financial metrics

Novo Nordisk Operating Metrics

FY, 2015FY, 2016

Patients Reached

26.80 m

Phase III Trials Products

6 3

Projects in R&D Pipeline

19 17
Show all operating metrics

Novo Nordisk Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Ziylo August 20, 2018$800 m
Report incorrect company information

Novo Nordisk Online and Social Media Presence

Embed Graph
Report incorrect company information

Novo Nordisk News and Updates

Denmark's Novo Nordisk buys UK insulin technology pioneer

Denmark's Novo Nordisk, the world's top insulin maker, said today it has acquired a British firm that is pioneering a new technology which could help people with diabetes inject themselves more safely with insulin. Novo Nordisk said in a statement it has acquired Bristol-based Ziylo in a deal that c…

Ziylo Acquired by Novo Nordisk in Deal That Could Exceed US$800m

BRISTOL, England, August 17, 2018 /PRNewswire/ -- Ziylo's technology platform could accelerate development of groundbreaking treatment for diabetes patients New company Carbometrics set up to develop novel diagnostics and glucose monitoring Unit DX, the scientific incubator in Bristol...

Diabetes Care Device 2018 Global Market Key Players - Dexcom, Novo Nordisk A/S, LifeScanInc, Roche Diagnostic, Bayer HealthCare, Terumo Corporation.....

Diabetes Care Device – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Novo Nordisk A/S: Bestyrelsesmedlemmers, koncerndirektørers og nærtstående personers handel med Novo Nordisk-aktier den 10. august 2018

Bagsværd, den 13. august 2018 - Dette dokument indeholder data om transaktioner vedrørende handel med Novo Nordisk-aktier udført af virksomhedens bestyrelsesmedlemmer, koncerndirektører og disses nærtstående i henhold til artikel 19 i forordningen om markedsmisbrug nr. 596/2014.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2018

Bagsværd, Denmark, 13 August 2018 - This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S - Aktietilbagekøbsprogram

Bagsværd, Danmark, den 10. august 2018 - Som led i det samlede aktietilbagekøbsprogram på op til 14 mia. kr. har Novo Nordisk A/S nu iværksat et nyt aktietilbagekøbsprogram på op til 2,4 mia. kr. i overensstemmelse med artikel 5 i Europa-Parlamentet og Rådets forordning (EU) nr. 596/2014 af 16. a…
Show more
Report incorrect company information

Novo Nordisk Company Life and Culture

Report incorrect company information